2 ms·
Can Open Source R&D reinvigorate Drug Research?
- EGreg 16y agoOpen source software grew out of the Free Software movement, which was modeled on the activities of scientists. Papers would be published in journals for everyone to read. It was free to teach a scientific theory to your students. Researchers built on each others' work. Drug research is scientific research. The distribution of drugs is actually pretty cheap -- once you know the formula, you can usually make the drug rather inexpensively. It's the R&D that needs funding, and it's currently funded by proprietary drug companies much like Microsoft, Adobe etc. built THEIR software. But years later, IE still sucks and open source browsers have helped the world a lot. Our mobile phones all run WebKit. We are lucky that Netscape open sourced their codebase and formed Mozilla, which at the time was an precedented move. These days, Apple, Google and Facebook work with the open source community, whereas Microsoft is becoming more and more irrelevant. If they joined with the open source communities instead of hiding their code they would probably bounce back -- for example if they threw out their old rendering engine and based IE10 on WebKit. Certainly patents and software help the old business models that rely on them (drug companies, newspapers, proprietary software companies). I think in software we have shown that over time, free information and community collaboration can produce better, more stable, more standards-compliant products. The question is, can we do this in other areas? I would argue that we have to separate the distribution network (Apple distributing apps, etc.) and the R&D. The distribution networks have to compete on price, efficiency, ease of access, etc. But the R&D is not necessarily done by drug companies. What happened to all that money we raise in "find the cure" walkathons? Where does it go? A lot of the drug research is done in universities, where papers are published openly and freely. I expect the drug companies to fight open source research just like Microsoft fought open source. But at the end of the day, there has to be a good system in place to fund R&D as a community that SHARES knowledge with the world. Don't get me wrong, clinical trials cost money, and dealing with the FDA costs money. But as far as innovation, there would be MORE innovation if people freely published the knowledge and built upon what others have done. You made a drug based on this gene sequence? I can make one that helps these gene sequences. That's the future, imho. The surprising truth about what motivates us: http://www.youtube.com/watch?v=u6XAPnuFjJc http://www.youtube.com/watch?v=u6XAPnuFjJc Smart people aren't just motivated by greed. Lots and lots of professors in university are motivated simply by making a difference in their field, and in their world. They want to make a breakthrough because they love their work. Sometimes they donate everything they get back to the university. Similarly, the kids who grew up with computers formed a hacker culture that loves to show off what they did to others. I think the first steps should be to foster that sort of "open source culture" among kids learning science in high school and college, and to provide the infrastructure for better online journals. When they finish grad school, they will often publish their research for free as a matter of helping the world. The drug companies won't be able to charge a huge markup on the drugs. The drugs would be manufactured at cost by the distribution networks (which are regulated by the government, of course, so no one slips a mickey in the drugs). A great example of an open source drug is this "cure for cancer" discovered in Canada: http://www.youtube.com/watch?v=7LXH-TJYS5w http://www.youtube.com/watch?v=7LXH-TJYS5w it may very well cure cancer in lots of different people. DCA has already been produced for over 100 years and no one can patent it. Which is great for the public at large. Imagine people taking DCA after the FDA has certified it, and it being produced cheaply. Basically, I think that we are just starting to see the ways in which a patent-less and copyright-less world can actually produce more innovation and useful solutions for people, than one where information is locked up in corporate silos and controlled by special interests.
- logjam 16y agoWell said. It is a colossal myth that pharma companies have to charge a lot for patented medications because of development costs (this is the story pushed, of course, by Big Pharma themselves). However, they spend most of their money on advertising: http://www.sciencedaily.com/releases/2008/01/080105140107.htm http://www.sciencedaily.com/releases/2008/01/080105140107.ht... Instead of innovation, a certain amount of pharma research is devoted near the end of a drug's patent lifetime to merely tweaking that established, well-studied drug a bit to produce a slightly different form. Product extensions with these slight modifications, generally of dubious benefit, can get at least 3 years of market exclusivity if their developments involve clinical research. Thus, what we get are slow rollouts of extended release, timed release, buffered, etc., etc., formulations of some old drug. Here's a good paper on some of the other strategies used by pharma to extend patent protection: http://nofta-ip.jinbo.net/files/Patent%20term%20extension%20strategies%20in%20the%20pharmaceutical%20industry.pdf http://nofta-ip.jinbo.net/files/Patent%20term%20extension%20... "Second, the pharmaceutical industry is not especially innovative. As hard as it is to believe, only a handful of truly important drugs have been brought to market in recent years, and they were mostly based on taxpayer-funded research at academic institutions, small biotechnology companies, or the National Institutes of Health (NIH). The great majority of “new” drugs are not new at all but merely variations of older drugs already on the market. These are called “me-too” drugs. The idea is to grab a share of an established, lucrative market by producing something very similar to a top-selling drug. For instance, we now have six statins (Mevacor, Lipitor, Zocor, Pravachol, Lescol, and the newest, Crestor) on the market to lower cholesterol, all variants of the first. As Dr. Sharon Levine, associate executive director of the Kaiser Permanente Medical Group, put it, If I’m a manufacturer and I can change one molecule and get another twenty years of patent rights, and convince physicians to prescribe and consumers to demand the next form of Prilosec, or weekly Prozac instead of daily Prozac, just as my patent expires, then why would I be spending money on a lot less certain endeavor, which is looking for brand-new drugs?" http://www.nybooks.com/articles/archives/2004/jul/15/the-truth-about-the-drug-companies/ http://www.nybooks.com/articles/archives/2004/jul/15/the-tru... A formed editor of the New England Journal of Medicine noted, "The combined profits for the ten drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion) [in 2002]. Over the past two decades the pharmaceutical industry has moved very far from its original high purpose of discovering and producing useful new drugs. Now primarily a marketing machine to sell drugs of dubious benefit, this industry uses its wealth and power to co-opt every institution that might stand in its way, including the US Congress, the FDA, academic medical centers, and the medical profession itself." http://www.wanttoknow.info/healthcoverup http://www.wanttoknow.info/healthcoverup